Bruns, Christiane; Schmidberger, Heinz; Schumacher-Schmidt, Stefanie
New course for <i>Die Onkologie</i>: the handover of editorship "There is nothing permanent except change" (Heraklit)ONKOLOGIE. Bd. 31. H. 1. 2025 S. 2-4
Hochhaus, Andreas; Niyazi, Maximilian; Schmidberger, Heinz
New drugs and new mechanisms of action in oncologyONKOLOGIE. Bd. 31. H. 5. 2025 S. 438-440
Fischer, Galina; Foersch, Sebastian; Eckhoff, Jennifer et al.
New journal section: "AI in oncology"ONKOLOGIE. Bd. 31. H. 6. 2025 S. 3
Stingl, Julia V.; Braun, Cordula; Walter, Sara et al.
New Threshold for Large Optic Discs in Children Using Bruch's Membrane Opening AreaTRANSLATIONAL VISION SCIENCE & TECHNOLOGY. Bd. 14. H. 4. 2025
Farmakis, Ioannis T.; Konstantinides, Stavros V.
NEWS in Action: Leveraging Serial Evaluation for Timely Intervention in Pulmonary Embolism ManagementTHROMBOSIS AND HAEMOSTASIS. 2025
Ali, Jamal; Bittel, Miriam; Huber, Yvonne et al.
NEXT GEN at Visceral Medicine 2025: A ReviewZEITSCHRIFT FUR GASTROENTEROLOGIE. Bd. 63. H. 10. 2025 S. 1088-1088
Wegner, Erik; Warnke, Dennis; Buschmann, Victoria et al.
Nintedanib reduces severity of post-traumatic joint contracture by modulating fibrosis and inflammationJOURNAL OF MOLECULAR MEDICINE-JMM. 2025
Kudo, Masatoshi; Yau, Thomas; Decaens, Thomas et al.
Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) therapy for unresectable hepatocellular carcinoma (uHCC): CheckMate 9DW expanded analyses.JOURNAL OF CLINICAL ONCOLOGY. Bd. 43. H. 4_SUPPL. 2025 S. 520-520
Yau, Thomas; Galle, Peter R.; Decaens, Thomas et al.
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3trialLANCET. Bd. 405. H. 10492. 2025 S. 1851-1864
Korkmaz, Yuksel; Kollmar, Tobias; Schultheis, Judith F. et al.
NO-cGMP Signaling in Endothelial Function of the Healthy and Inflamed Dental PulpINTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. Bd. 27. H. 1. 2025